Evidence check: SHBG in the context of blood sugar

SHBG (sex hormone-binding globulin) is frequently discussed in relation to blood sugar and insulin resistance. Epidemiological studies consistently show an inverse association: low SHBG levels are linked to increased risk of type 2 diabetes and metabolic syndrome. Mechanistically, insulin is thought to suppress hepatic SHBG production, while SHBG itself may modulate insulin sensitivity. However, SHBG is not a direct causal factor – it is more a biomarker modulated by lifestyle (diet, exercise, body fat) and hormonal status (estrogens, androgens). Evidence comes from large cohorts (e.g., EPIC, NHANES) and meta-analyses, thus rated human-strong. Caveat: single SHBG measurements are variable; clinical decisions should rely on fasting glucose, HbA1c, and oral glucose tolerance test. Genetic variants (e.g., in the SHBG gene) have small effects and are not actionable. MyBody-X offers SHBG as a biomarker but not via DNA testing. Interpretation must always consider other metabolic parameters.